ArticlePharmacoEconomics2023

Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.

Amy Gye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.